Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 14 February 2017 | By Zachary Brennan
The European Medicines Agency (EMA) signaled Tuesday that doctors can continue to use Actelion Pharmaceuticals’ pulmonary arterial hypertension (PAH) medicine Uptravi (selexipag) while the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) evaluates its safety following the deaths of five patients taking the medicine in France.
“Based on a preliminary review of available data, EMA advises that Uptravi may continue to be used, both in existing and new patients, but use must be in line with the current prescribing information,” EMA said in a statement.
First approved in the EU on 12 May 2016 (and in the US on 22 December 2015), Uptravi belongs to a class of drugs called oral IP prostacyclin receptor agonists. According to the US Food and Drug Administration, the drug “acts by relaxing muscles in the walls of blood vessels to dilate (open) blood vessels and decrease the elevated pressure in the vessels supplying blood to the lungs.”
EMA’s PRAC says it will further explore all available data in its review and, once completed, final conclusions will be published. The PRAC review follows a letter sent last month from France's drug regulator, known as ANSM, alerting health professionals to the issues mentioned by EMA.
“While the review is ongoing, EMA advises that doctors prescribing Uptravi carefully follow recommendations and precautions in the current prescribing information,” EMA said in a statement. “Patients taking Uptravi should follow their doctors’ instructions and can continue treatment with the medicine. Patients who have any questions about their treatment should speak to their doctor or pharmacist.”
Last Friday, PRAC also warned of “an increase in cases of lower limb amputation, mostly affecting the toes, has been observed in patients taking the type 2 diabetes medicine canagliflozin compared with those taking placebo.”
Tags: Uptravi, PRAC, Actelion
Regulatory Focus newsletters
All the biggest regulatory news and happenings.